Literature DB >> 6819901

Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD.

C G Nilsson, M Haukkamaa, H Vierola, T Luukkainen.   

Abstract

Thirteen women who were scheduled for hysterectomy volunteered for the study. Nine women had a levonorgestrel-releasing intrauterine contraceptive device inserted between 36 and 49 days prior to surgery and four women were on oral levonorgestrel treatment for 7 days prior to surgery. After the surgical removal of the uterus, samples of endometrial, myometrial, fallopian tube and fat tissue were obtained. Methods for measuring tissue concentrations of levonorgestrel were developed and the uptake of levonorgestrel by fat tissue in vitro was studied. The concentrations of levonorgestrel in myometrial, fallopian tube and fat tissue were all of the same order, of between 1 and 5 ng/g of wet weight of tissue, in both the intrauterine device group and the orally treated group. In the endometrium the levonorgestrel concentrations were many-fold higher in the intrauterine device group. The in vitro experiments showed a rapid uptake of levonorgestrel and an unsaturability of the fat tissue by the steroid at the concentrations used. The fat tissue concentrations of levonorgestrel correlated with the plasma concentrations.

Entities:  

Keywords:  Biology; Clinical Research; Contraception; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Agents--analysis; Contraceptive Methods; Endometrium--analysis; Examinations And Diagnoses; Fallopian Tubes--analysis; Family Planning; Genitalia; Genitalia, Female; Histology; Human Volunteers; Iud; Iud, Hormone Releasing; Laboratory Examinations And Diagnoses; Laboratory Procedures; Levonorgestrel--analysis; Myometrial Effects; Myometrium; Physiology; Reproductive Control Agents; Research Methodology; Size; Urogenital System; Uterus

Mesh:

Substances:

Year:  1982        PMID: 6819901     DOI: 10.1111/j.1365-2265.1982.tb01625.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  28 in total

1.  Risk of intracranial hypertension with intrauterine levonorgestrel.

Authors:  Mahyar Etminan; Hao Luo; Paul Gustafson
Journal:  Ther Adv Drug Saf       Date:  2015-06

Review 2.  Challenges in the gynecologic care of premenopausal women with breast cancer.

Authors:  Jamie N Bakkum-Gamez; Shannon K Laughlin; Jani R Jensen; Clement O Akogyeram; Sandhya Pruthi
Journal:  Mayo Clin Proc       Date:  2011-02-09       Impact factor: 7.616

Review 3.  A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.

Authors:  F Sturridge; J Guillebaud
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

Review 4.  Efficacy and safety of long-acting reversible contraception.

Authors:  Amy Stoddard; Colleen McNicholas; Jeffrey F Peipert
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

5.  Benefit-risk assessment of the levonorgestrel intrauterine system in contraception.

Authors:  Tiina Backman
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 6.  Long-acting reversible contraception for adolescents.

Authors:  Colleen McNicholas; Jeffrey F Peipert
Journal:  Curr Opin Obstet Gynecol       Date:  2012-10       Impact factor: 1.927

7.  Successful treatment of early endometrial carcinoma by local delivery of levonorgestrel: a case report.

Authors:  D Wildemeersch; E Anderson; K Lambein; P Pauwels; M Dhont
Journal:  Obstet Gynecol Int       Date:  2010-10-20

8.  Risk of urinary incontinence symptoms in oral contraceptive users: a national cohort study from the Swedish Twin Register.

Authors:  Anastasia Iliadou; Ian Milsom; Nancy L Pedersen; Daniel Altman
Journal:  Fertil Steril       Date:  2008-08-15       Impact factor: 7.329

Review 9.  Clarification of contraceptive drug pharmacokinetics in obesity.

Authors:  William J Jusko
Journal:  Contraception       Date:  2016-08-16       Impact factor: 3.375

10.  Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy.

Authors:  Rachel S Mandelbaum; Marcia A Ciccone; David J Nusbaum; Mahdi Khoshchehreh; Heena Purswani; Elise B Morocco; Meghan B Smith; Shinya Matsuzaki; Christina E Dancz; Begum Ozel; Lynda D Roman; Richard J Paulson; Koji Matsuo
Journal:  Am J Obstet Gynecol       Date:  2020-01-21       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.